Shire Sues Nostrum Pharma Over ANDA For Epilepsy Drug

Law360, New York (January 14, 2004, 12:00 AM EST) -- U.K. drug maker Shire Pharmaceuticals Group has sued Nostrum Pharmaceuticals over its plans to produce a generic version of Shire’s epilepsy drug Carbatrol.

The lawsuit was filed in the U.S. District Court for the District of New Jersey.

Patents on Carbatrol, an anti-convulsant that generated sales of $45 million in 2002, expire in 2011 and 2019.

Shire made total drug sales of $859 million in 2002.

The lawsuit results from an Abbreviated New Drug Application(ANDA) filed by Nostrum for a generic version of the 300 mg...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.